Exact Mass: 522.1861
Exact Mass Matches: 522.1861
Found 157 metabolites which its exact mass value is equals to given mass value 522.1861
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Ticagrelor
Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
Prednisolone phthalate
5-Hydroxy-7-methoxy-3,4-diacetoxy-6-(6,6-dimethyl-2-oxo-cyclohexylmethyl)flavone
1beta-(3-furanoyloxy)-9alpha-benzoyloxy-8beta-acetoxy-2-oxo-3-enedihydro-beta-agarofuran
Ticagrelor
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
C22H34O14_Hexitol, 2,6-anhydro-, 5-[4-(beta-D-glucopyranosyloxy)-2-methylenebutanoate] 1-(4-hydroxy-2-methylenebutanoate)
Cys His Thr Tyr
Cys His Tyr Thr
Cys Asn Thr Trp
Cys Asn Trp Thr
Cys Gln Ser Trp
Cys Gln Trp Ser
Cys Ser Gln Trp
Cys Ser Trp Gln
Cys Thr His Tyr
Cys Thr Asn Trp
Cys Thr Trp Asn
Cys Thr Tyr His
Cys Trp Asn Thr
Cys Trp Gln Ser
Cys Trp Ser Gln
Cys Trp Thr Asn
Cys Tyr His Thr
Cys Tyr Thr His
Asp Asp His His
Asp His Asp His
Asp His His Asp
His Cys Thr Tyr
His Cys Tyr Thr
His Asp Asp His
His Asp His Asp
His His Asp Asp
His Thr Cys Tyr
His Thr Tyr Cys
His Tyr Cys Thr
His Tyr Thr Cys
Met Met Asn Gln
Met Met Gln Asn
Met Asn Met Gln
Met Asn Gln Met
Met Gln Met Asn
Met Gln Asn Met
Asn Cys Thr Trp
Asn Cys Trp Thr
Asn Met Met Gln
Asn Met Gln Met
Asn Gln Met Met
Asn Thr Cys Trp
Asn Thr Trp Cys
Asn Trp Cys Thr
Asn Trp Thr Cys
Gln Cys Ser Trp
Gln Cys Trp Ser
Gln Met Met Asn
Gln Met Asn Met
Gln Asn Met Met
Gln Ser Cys Trp
Gln Ser Trp Cys
Gln Trp Cys Ser
Gln Trp Ser Cys
Ser Cys Gln Trp
Ser Cys Trp Gln
Ser Gln Cys Trp
Ser Gln Trp Cys
Ser Trp Cys Gln
Ser Trp Gln Cys
Thr Cys His Tyr
Thr Cys Asn Trp
Thr Cys Trp Asn
Thr Cys Tyr His
Thr His Cys Tyr
Thr His Tyr Cys
Thr Asn Cys Trp
Thr Asn Trp Cys
Thr Trp Cys Asn
Thr Trp Asn Cys
Thr Tyr Cys His
Thr Tyr His Cys
Trp Cys Asn Thr
Trp Cys Gln Ser
Trp Cys Ser Gln
Trp Cys Thr Asn
Trp Asn Cys Thr
Trp Asn Thr Cys
Trp Gln Cys Ser
Trp Gln Ser Cys
Trp Ser Cys Gln
Trp Ser Gln Cys
Trp Thr Cys Asn
Trp Thr Asn Cys
Tyr Cys His Thr
Tyr Cys Thr His
Tyr His Cys Thr
Tyr His Thr Cys
Tyr Thr Cys His
Tyr Thr His Cys
1,1-(Decane-1,10-diyl)bis[4-aza-1-azoniabicyclo[2.2.2]octane] Dibromide
2-methyl-6-phenyl-4-(2-phenylethynyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O3-ethyl ester O5-[(4-nitrophenyl)methyl] ester
MRS1334 is a potent and selective human adenosine A3 receptor antagonist with Kis of 2.69 nM, >100 nM, >100 nM for hA3, rA1, rA2A, respectively. MRS1334 blocks the protective effect of Cl-IB-MECA leading to significant bradycardia and elevated ST segment[1][2]. MRS1334 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
N-alpha-(2-Naphthylsulfonyl)-N(3-amidino-L-phenylalaninyl)isopipecolinic acid methyl ester
23,26-Dihydroxy-23-(2-hydroxyacetyl)-1,24-dimethyl-3,12-dioxahexacyclo[14.11.0.02,13.05,10.019,27.020,24]heptacosa-2(13),5,7,9,15-pentaene-4,11,14-trione
[3,4-dihydroxy-5-[2-methylidene-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanoyl]oxyoxan-2-yl]methyl 4-hydroxy-2-methylidenebutanoate
4-methyl-N-[5-[2-[2-[[1-[(4-methylphenyl)methyl]indol-3-yl]methylidene]hydrazinyl]-2-oxidanylidene-ethyl]-1,3,4-thiadiazol-2-yl]benzamide
9-[5-Carboxy-2-(ethoxycarbonyl)phenyl]-3,6-bis(ethylamino)-2,7-dimethylxanthenium chloride
[(1R)-2-[(4-chlorophenyl)methyl]-7-methoxy-1-(2-thiazolylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
1-(4-fluorophenyl)-3-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
[(1S)-2-[(4-chlorophenyl)methyl]-7-methoxy-1-(2-thiazolylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
1-(4-fluorophenyl)-3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
1-(4-fluorophenyl)-3-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
1-(4-fluorophenyl)-3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
1-(4-fluorophenyl)-3-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
(1R,2S,3R,5S)-3-[7-[[(1R,2R)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,4as,7r,7ar)-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-carboxylate
5-hydroxy-7-methoxy-3',4'-diacetoxy-6-(6,6-dimethyl-2-oxo-cyclohexylmethyl)flavone
{"Ingredient_id": "HBIN011655","Ingredient_name": "5-hydroxy-7-methoxy-3',4'-diacetoxy-6-(6,6-dimethyl-2-oxo-cyclohexylmethyl)flavone","Alias": "NA","Ingredient_formula": "C29H30O9","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10396","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}